U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C21H28N2O2
Molecular Weight 340.4592
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DECLOXIZINE

SMILES

OCCOCCN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=OXBBIHZWNDPBMQ-UHFFFAOYSA-N
InChI=1S/C21H28N2O2/c24-16-18-25-17-15-22-11-13-23(14-12-22)21(19-7-3-1-4-8-19)20-9-5-2-6-10-20/h1-10,21,24H,11-18H2

HIDE SMILES / InChI
Molecular Formula C21H28N2O2
Molecular Weight 340.4592
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Decloxizine (UCB-1402; NSC289116) is a histamine 1 receptor antagonist. Decloxizine is a broncholyticum.

CNS Activity

CNS Active
4,002

Approval Year

Unknown
149,124

Targets

Primary TargetPharmacologyConditionPotency
Histamine H1 receptor
316
Antagonist
2,849

Conditions

ConditionModalityTargetsHighest PhaseProduct
Bronchitis
51
 Primary
Preclinical
Unknown
Asthma
244
 Primary
Preclinical
Unknown

PubMed

Patents

06903118
3

Sample Use Guides

In Vivo Use Guide
Three daily 50 mg doses of decloxizine proved sufficient to prevent asthma attacks and shortness of breath in the patients examined
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
919C49XAYD
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966